Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease – Prime Medicine (NASDAQ:PRME)Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease – Prime Medicine (NASDAQ:PRME)
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new{...}